Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 9

1.

The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring.

Gatti G, Di Biagio A, Casazza R, De Pascalis C, Bassetti M, Cruciani M, Vella S, Bassetti D.

AIDS. 1999 Oct 22;13(15):2083-9.

PMID:
10546861
2.

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients.

Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM.

AIDS. 1999 Mar 11;13(4):473-8.

PMID:
10197375
3.

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.

Kline MW, Fletcher CV, Harris AT, Evans KD, Brundage RC, Remmel RP, Calles NR, Kirkpatrick SB, Simon C.

J Pediatr. 1998 Mar;132(3 Pt 1):543-6.

PMID:
9544920
4.

Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors.

Melvin AJ, Mohan KM, Arcuino LA, Edelstein RE, Frenkel LM.

Pediatr Infect Dis J. 1997 Oct;16(10):968-74.

PMID:
9380474
5.

Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience.

Monpoux F, Sirvent N, Cottalorda J, Mariani R, Lefbvre JC.

AIDS. 1997 Oct;11(12):1523-5. No abstract available.

PMID:
9342078
6.

Protease inhibitor therapy in children with perinatally acquired HIV infection.

Rutstein RM, Feingold A, Meislich D, Word B, Rudy B.

AIDS. 1997 Oct;11(12):F107-11.

PMID:
9342062
7.

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.

Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA.

JAMA. 1997 Jun 25;277(24):1962-9.

PMID:
9200638
8.

A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL.

AIDS. 1996 May;10(5):485-92.

PMID:
8724039
9.

L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.

Dorsey BD, Levin RB, McDaniel SL, Vacca JP, Guare JP, Darke PL, Zugay JA, Emini EA, Schleif WA, Quintero JC, et al.

J Med Chem. 1994 Oct 14;37(21):3443-51.

PMID:
7932573
Items per page

Supplemental Content

Write to the Help Desk